Company Filing History:
Years Active: 2012-2013
Title: Debra Ainge: Innovator in Pharmaceutical Chemistry
Introduction
Debra Ainge is a prominent inventor based in Leicestershire, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. Her work has led to the filing of multiple patents, showcasing her innovative approach to drug development.
Latest Patents
Debra Ainge holds 2 patents that focus on the synthesis of specific compounds. One of her latest patents involves the creation of 2-pyrazinone derivatives, which serve as inhibitors of human neutrophil elastase. This invention provides novel compounds and their pharmaceutically acceptable salts, along with processes for their preparation and use in therapy. The compounds are designed to inhibit human neutrophil elastase, which plays a role in various inflammatory conditions. Another patent relates to pharmaceutical processes and intermediates, detailing compounds that serve as intermediates in improved manufacturing processes for synthesizing pharmaceutical compounds.
Career Highlights
Debra Ainge has established herself as a key figure in the pharmaceutical industry. Her work at AstraZeneca has allowed her to contribute to significant advancements in drug development. Her innovative research has not only led to patents but has also influenced the direction of therapeutic strategies in treating various diseases.
Collaborations
Throughout her career, Debra has collaborated with notable colleagues, including David Chapman and Martin Lindsjö. These partnerships have enhanced her research and contributed to the successful development of her patented inventions.
Conclusion
Debra Ainge's contributions to pharmaceutical chemistry through her innovative patents and collaborations highlight her role as a leading inventor in the field. Her work continues to impact therapeutic development and showcases the importance of innovation in medicine.